NasdaqGS:NRC

Stock Analysis Report

Executive Summary

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada.

Snowflake

Fundamentals

Solid track record with imperfect balance sheet.

Risks

  • National Research is not covered by any analysts.

Share Price & News

How has National Research's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.0%

NRC

-0.3%

US Healthcare

-0.6%

US Market


1 Year Return

61.5%

NRC

-9.2%

US Healthcare

0.7%

US Market

NRC outperformed the Healthcare industry which returned -9.1% over the past year.

NRC outperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

NRCIndustryMarket
7 Day2.0%-0.3%-0.6%
30 Day1.0%2.1%4.9%
90 Day15.1%-0.8%1.7%
1 Year66.6%61.5%-7.8%-9.2%3.0%0.7%
3 Year325.7%299.5%29.7%24.4%44.8%35.4%
5 Year420.9%362.2%66.1%56.2%62.0%44.3%

Price Volatility Vs. Market

How volatile is National Research's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is National Research undervalued based on future cash flows and its price relative to the stock market?

54.85x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

National Research's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

National Research's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

National Research is overvalued based on earnings compared to the US Healthcare industry average.

National Research is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for National Research, we can't assess if its growth is good value.


Price Based on Value of Assets

National Research is overvalued based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is National Research expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

-35.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if National Research is high growth as no revenue estimate data is available.

National Research's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.

Unable to compare National Research's revenue growth to the United States of America market average as no estimate data is available.

National Research's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.

National Research's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if National Research will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has National Research performed over the past 5 years?

13.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

National Research's year on year earnings growth rate has been positive over the past 5 years.

National Research's 1-year earnings growth exceeds its 5-year average (17.4% vs 13.5%)

National Research's earnings growth has exceeded the US Healthcare industry average in the past year (17.4% vs 5.6%).


Return on Equity

Whilst National Research made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%), this is metric is skewed due to its high level of debt.


Return on Assets

National Research used its assets more efficiently than the US Healthcare industry average last year based on Return on Assets.


Return on Capital Employed

National Research has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is National Research's financial position?


Financial Position Analysis

National Research's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

National Research's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

National Research's level of debt (142.6%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (11.2% vs 142.6% today).

Debt is well covered by operating cash flow (101.4%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 18.4x coverage).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.6x debt.


Next Steps

Dividend

What is National Research's current dividend yield, its reliability and sustainability?

1.21%

Current Dividend Yield


Upcoming Dividend Payment

Purchase National Research before the 'Buy Limit' to receive their next dividend payment.


Dividend Yield and Payments Analysis

National Research's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).

National Research's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).

National Research has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).

National Research has only been paying a dividend for 5 years, and since then dividends per share have fallen.


Current Payout to Shareholders

Dividends paid are covered by earnings (1.5x coverage).


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of National Research's salary, the management and board of directors tenure and is there insider trading?

6.0yrs

Average management tenure


CEO

Mike Hays (64yo)

38.7yrs

Tenure

US$289,467

Compensation

Mr. Michael D. Hays, also known as Mike, serves as an Advisor of Picker Institute Inc. Mr. Hays founded National Research Corp. in 1981 and has been its Chief Executive Officer since 1981. Mr. Hays served  ...


CEO Compensation Analysis

Mike's remuneration is lower than average for companies of similar size in United States of America.

Mike's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.


Management Age and Tenure

6.0yrs

Average Tenure

61yo

Average Age

The average tenure for the National Research management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

7.3yrs

Average Tenure

66yo

Average Age

The tenure for the National Research board of directors is about average.


Insider Trading

National Research individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$391,53120 Sep 19
Amandla MK Trust
EntityCompany
Shares6,200
Max PriceUS$63.15
SellUS$24,13020 Sep 19
Steven Jackson
EntityIndividual
Role
President
President
Shares380
Max PriceUS$63.50
SellUS$155,00019 Sep 19
Steven Jackson
EntityIndividual
Role
President
President
Shares2,500
Max PriceUS$62.00
SellUS$30,252,05019 Sep 19
Michael Hays
EntityIndividual
Role
Chief Executive Officer
Founder
Shares500,000
Max PriceUS$60.50
SellUS$433,43718 Sep 19
Donald Berwick
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares6,992
Max PriceUS$61.99
SellUS$155,00018 Sep 19
Steven Jackson
EntityIndividual
Role
President
President
Shares2,500
Max PriceUS$62.00
SellUS$433,58317 Sep 19
Donald Berwick
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares6,989
Max PriceUS$62.04
SellUS$181,25916 Sep 19
Donald Berwick
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares2,924
Max PriceUS$61.99
SellUS$69,42913 Sep 19
Donald Berwick
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,120
Max PriceUS$61.99
SellUS$182,33809 Sep 19
Kevin Karas
EntityIndividual
Role
Chief Financial Officer
Senior VP of Finance
Shares2,902
Max PriceUS$62.83
SellUS$569,30509 Sep 19
Donald Berwick
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares9,035
Max PriceUS$63.01
SellUS$455,05506 Sep 19
Kevin Karas
EntityIndividual
Role
Chief Financial Officer
Senior VP of Finance
Shares7,114
Max PriceUS$64.34
SellUS$68,93205 Sep 19
Michael Hays
EntityIndividual
Role
Chief Executive Officer
Founder
Shares1,063
Max PriceUS$64.85
SellUS$2,191,54504 Sep 19
Michael Hays
EntityIndividual
Role
Chief Executive Officer
Founder
Shares33,800
Max PriceUS$64.84
SellUS$181,70330 Aug 19
Michael Hays
EntityIndividual
Role
Chief Executive Officer
Founder
Shares2,800
Max PriceUS$64.89
SellUS$15,876,42829 Aug 19
Michael Hays
EntityIndividual
Role
Chief Executive Officer
Founder
Shares252,000
Max PriceUS$63.00
SellUS$819,90923 Aug 19
Michael Hays
EntityIndividual
Role
Chief Executive Officer
Founder
Shares12,648
Max PriceUS$64.83
SellUS$58,05021 Aug 19
Michael Hays
EntityIndividual
Role
Chief Executive Officer
Founder
Shares900
Max PriceUS$64.50
SellUS$1,032,56619 Aug 19
Michael Hays
EntityIndividual
Role
Chief Executive Officer
Founder
Shares15,961
Max PriceUS$64.74
SellUS$1,229,67216 Aug 19
Michael Hays
EntityIndividual
Role
Chief Executive Officer
Founder
Shares19,000
Max PriceUS$64.97

Ownership Breakdown


Management Team

  • Mike Hays (64yo)

    Founder

    • Tenure: 38.7yrs
    • Compensation: US$289.47k
  • Kevin Karas (61yo)

    Senior VP of Finance

    • Tenure: 8yrs
    • Compensation: US$644.61k
  • Steve Jackson (43yo)

    President

    • Tenure: 3.9yrs
    • Compensation: US$676.61k
  • Helen Hrdy

    Senior Vice President of Client Services

    • Tenure: 3.7yrs

Board Members

  • Mike Hays (64yo)

    Founder

    • Tenure: 38.7yrs
    • Compensation: US$289.47k
  • Barbara Mowry (71yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: US$150.02k
  • John Nunnelly (66yo)

    Lead Director

    • Tenure: 7.3yrs
    • Compensation: US$175.02k
  • JoAnn Martin (64yo)

    Independent Director

    • Tenure: 18.3yrs
    • Compensation: US$150.02k
  • Don Berwick (72yo)

    Independent Director

    • Tenure: 3.9yrs
    • Compensation: US$150.02k

Company Information

National Research Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: National Research Corporation
  • Ticker: NRC
  • Exchange: NasdaqGS
  • Founded: 1981
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$1.554b
  • Shares outstanding: 24.80m
  • Website: https://nrchealth.com

Number of Employees


Location

  • National Research Corporation
  • 1245 Q Street
  • Lincoln
  • Nebraska
  • 68508
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NRCNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2013
NR1ABST (Boerse-Stuttgart)YesCommon StockDEEURMay 2013

Biography

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscripti ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/23 00:31
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.